EU Approves Sanofi's (SNY) Sarclisa for Newly Diagnosed Multiple Myeloma Patients

Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts. On July 25, Sanofi (NASDAQ:SNY) announced that Sarclisa, one of its medications, has been approved by the European Union for the treatment of newly diagnosed multiple myeloma patients who are eligible for transplantation. The approval significantly broadens the scope of treatment for Sarclisa by extending its use across all therapeutic lines in the EU.

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) negativity, a crucial indicator of how well a treatment is working for patients with multiple myeloma.

With this regulatory milestone, Sarclisa’s approvals have been expanded to include multiple myeloma patients at different phases of their treatment cycle within the European Union.

Sanofi (NASDAQ:SNY) is a leading French healthcare company. Its primary goal is to enhance patient health through research, development, production, and promotion of a variety of therapeutic options.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.